

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 28, 2021

**PROPHASE LABS, INC.**

(Exact name of Company as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of incorporation)

**000-21617**  
(Commission  
File Number)

**23-2577138**  
(I.R.S. Employer  
Identification No.)

**711 Stewart Ave.,  
Garden City, NY**  
(Address of principal executive offices)

**11530**  
(Zip Code)

Company's telephone number, including area code: **(215) 345-0919**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value \$0.0005	PRPH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

On May 28, 2021, ProPhase Labs, Inc. (the "Company") issued a press release announcing that Ted Karkus, the Company's Chief Executive Officer, will present at the LD Micro Invitational XI virtual conference taking place June 8-10, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including the exhibit, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

Exhibit Number	Exhibit Table
-------------------	---------------

99.1 [Press Release issued by ProPhase Labs, Inc., dated May 28, 2021.](#)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ProPhase Labs, Inc.**

By: /s/ Monica Brady  
Monica Brady  
Chief Financial Officer

---

Date: May 28, 2021

---

**ProPhase Labs to Present at LD Micro Invitational XI Virtual Conference**

*CEO Ted Karkus to Present at Conference on Thursday, June 10th, 2021*

**GARDEN CITY, NY, May 28, 2021** — ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced that CEO Ted Karkus will present at the LD Micro Invitational XI virtual conference taking place June 8-10, 2021.

Ted Karkus, Chief Executive Officer, is scheduled to host a virtual presentation during the event as follows:

**2021 LD Micro Invitational XI**

Date: Thursday, June 10, 2021

Time: 1:00 p.m. EDT – Track 2

Webcast: <https://ldmicrojune2021.mysequire.com>

A live audio webcast and archive of the event presentation will be available using the webcast link above. For more information on the LD Micro Invitational XI, or to register for the event, please visit <https://ldmicrojune2021.mysequire.com>.

**About ProPhase Labs**

ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company. The Company's subsidiary, ProPhase Diagnostics, offers a broad array of clinical diagnostic insights and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients with SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Our methodology also has the capability to identify the possibility of mutations. Critical to COVID testing, results are provided in under 24 hours. ProPhase now also offers antigen tests for COVID-19 and polymerase chain reaction (PCR) for Influenza A and B and RSV. We also are currently developing an immunity test. ProPhase Labs researches, develops, manufactures, distributes, markets, and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. The Company actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit [www.ProPhaseLabs.com](http://www.ProPhaseLabs.com).

**Investor Contact**

Chris Tyson  
Managing Director  
MZ Group - MZ North America  
949-491-8235  
[PRPH@mzgroup.us](mailto:PRPH@mzgroup.us)  
[www.mzgroup.us](http://www.mzgroup.us)

---